Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMS-01940153E in previously treated unresectable HCC
NCT05630937Phase 2Terminated
- Sponsor
- Nerviano Medical Sciences
- Start
- Nov 2020
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of s 81694 in hepatocellular carcinoma (HCC), sponsored by Nerviano Medical Sciences. Primary endpoints: Dose Limiting Toxicities at 28 days and Objective Response Rate at 23 months. Started Nov 2020; status: terminated.
02
Drugs
s 81694
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05630937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630937.